The Defense Health Agency awarded The Medical University of South Carolina $140,000 on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support modeling BRAFV600E-driven hepatic Langerhans cell histiocytosis using human iPSC-derived in vitro and in vivo platforms. The award supports basic and applied biomedical research aimed at transforming healthcare for Service Members through innovative research and investigating medical solutions relevant to military health priorities. Work is performed in Charleston, South Carolina, with a period of performance extending through October 31, 2028. This modification corrected the effective date to November 1, 2026, and updated Division I items in the award document.